Identification and quantification of selected inflammatory genes modulated by leflunomide and prednisone treatment in early rheumatoid arthritis patients

Clinical and Experimental Rheumatology

Volumn 29, Issue 1, 2011, Pages 72-79

  Cutolo, Maurizio ^a   Villaggio, Barbara ^a   Brizzolara, Renata ^a   Montagna, Paola ^a   Gallo, Fabio ^b   Moretti, Stefano ^c,d   Bonassi, Stefano ^e   Sulli, Alberto ^a   Soldano, Stefano ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c CNRS   (France)

^d UNIVERSITÉ PARIS DAUPHINE   (France)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Gene microarray; Gene profile expression; Glucocorticoids; Inflammation; Leflunomide; Rheumatoid arthritis

Indexed keywords

CYTOKINE; LEFLUNOMIDE; PREDNISONE; GLUCOCORTICOID; ISOXAZOLE DERIVATIVE; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; TRANSCRIPTION FACTOR;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HIF1A GENE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIMIT OF QUANTITATION; LOW DRUG DOSE; MACROPHAGE MIGRATION INHIBITORY FACTOR GENE; MALE; MAPK9 GENE; MICROARRAY ANALYSIS; NUCLEAR FACTOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B CELL 1 GENE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 4 GENE; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 GENE; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1B GENE; UPREGULATION; DRUG COMBINATION; DRUG POTENTIATION; GENETICS; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ARTHRITIS, RHEUMATOID; CYTOKINES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION PROFILING; GLUCOCORTICOIDS; HUMANS; ISOXAZOLES; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PREDNISONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNOVITIS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 79955666189     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. SILMAN AJ, PEARSON JE: Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002; 4: S265-72.
2. FIRESTEIN GS: Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
3. BOWERS J, BARTON A: Recent advances in the genetics of RA susceptibility. Rheumatology 2008; 47: 399-402.
4. CUTOLO M, STRAUB RH: Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment. Arthritis Res Ther 2009; 11: 218-22.
5. JUNTA CM, SANDRIN-GARCIA P, FACHINSALTORATTO AL et al.: Differential gene expression of peripheral blood mononuclear cells from rheumatoid arthritis patients may discriminate immunogenic, pathogenic and treatment features. Immunology 2009; 127: 365-72.
6. BURMESTER GR, HAUPL T: Strategies using functional genomics in rheumatic diseases. Autoimmun Rev 2004; 3: 541-9.
7. MARKATSELI TE, PAPAGORAS C, DROSOS AA: Prognostic factors for erosive rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 114-23.
8. SMOLEN JS, LANDEWÉ R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
9. DAYER JM: The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract Res Clin Rheumatol 2004; 18: 31-45.
10. GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS: ACR Subcommittee. Arthrit Rheum 2002; 46: 328-46.
11. TOONEN EJ, BARRERA P, RADSTAKE TR et al.: Gene expression profiling in rheumatoid arthritis: current concepts and future directions. Ann Rheum Dis 2008; 67: 1663-9.
12. SCHENA M, SHALON D, DAVIS RW, BROWN PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467-70.
13. OLSEN N, SOKKA T, SEEHORN CL et al.: A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis 2004 63: 1387-92.
14. SEKIGUCHI N, KAWAUCHI S, FURUYA T et al.: Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford) 2008; 47: 780-8.
15. LINDBERG J, WIJBRANDTS CA, VAN BAARSEN LG et al.: The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis. PLoS One 2010; 5:e11310"in press".
16. VAN BAARSEN LG, BOS WH, RUSTENBURG F et al.: Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum 2010; 62: 694-704.
17. HO CY, WONG CK, LI EK, TAM LS, LAM CW: Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis. Clin Exp Immunol 2003; 133: 132-8.
18. CUTOLO M, VILLAGGIO B, PIZZORNI C et al.: Inflammatory gene profile in early rheumatoid arthritis and modulation by leflunomide and prednisone treatment. Ann N Y Acad Sci 2010; 1193: 15-21.
19. IHAKA R, GENTLEMAN R: R: A language for data analysis and graphics. Journal of Computational and Graphical Statistics. 1996; 5: 299-314.
20. WARD JH: Hierarchical grouping to optimize an objective function. J Am Stat Assoc 1963; 58: 236-44.
21. FISHER RA: The logic of inductive inference. Journal of the Royal Statistical Society Series A 1935; 98: 39-54.
22. -ΔΔCt method. Methods 2001; 25: 402-8.
23. AYOUB S, HICKEY MJ, MORAND EF: Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nat Clin Pract Rheumatol 2008; 4: 98-105.
24. KIYOHARA C, WASHIO M, HORIUCHI T et al.: Cigarette smoking, STAT4 and TNFRSF1B polymorphisms, and systemic lupus erythematosus in a Japanese population. J Rheumatol 2009; 36: 2195-203.
25. LEE EG, BOONE DL, CHAI S et al.: Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 29: 2350-4.
26. BROUWER E, GOUW AS, POSTHUMUS MD et al.: Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 945-51.
27. HÄULP T, STUHLMULLER B, GRUTZKAU A, RADBRUCH A, BURMESTER GR: Does gene expression analysis inform us in rheumatoid arthritis? Ann Rheum Dis 2010; 69 (Suppl. I): i37-i42.
28. LEQUERRE T, BANSARD C, VITTECOQ O et al.: Early and long-standing rheumatoid arthritis: distinct molecular signatures identified by gene-expression profiling in synovia. Arthritis Res Ther 2009; 11: R99
29. SCHURIGT U, PFIRSCHKE C, IRMLER IM et al.: Interactions of T helper cells with fibroblast-like synoviocytes: up-regulation of matrix metalloproteinases by macrophage migration inhibitory factor from both Th1 and Th2 cells. Arthritis Rheum 2008; 58: 3030-40.
30. MARTINEZ A, OROZCO G, VARADE J et al.: Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Human Immunol 2007; 68: 744-7.
31. WINNER M, KOONG AC, RENDON BE, ZUNDEL W, MITCHELL RA: Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Research 2007; 67: 186-93.
32. SCHETT G, TOHIDAST-AKRAD M, SMOLEN JS et al.: Activation, differential localization, and regulation of the stress-activated kinases, extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 mitogen activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2501-12.
33. LEE CK, LEE EY, KIM YG, MUN SH, MOON HB, YOO B: Alpha-lipoic acid inhibits TNFalpha induced NF-kappa B activation through blocking of MEKK1-MKK4-IKK signaling cascades. Int Immunopharmacol 2008; 8: 362-70.
34. FIRESTEIN GS: NF-kappaB: Holy Grail for rheumatoid arthritis? Arthritis Rheum 2004; 50: 2381-6
35. LI X, YANG Y, ASHWELL JD: TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 2002; 416: 345-7.
36. DIEGUEZ-GONZALEZ R, CALAZA M, PEREZPAMPIN E et al.: Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-kB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthritis Res Ther 2009;11:R42.
37. PALAO G, SANTIAGO B, GALINDO M et al.: Fas activation of a proinflammatory program in rheumatoid synoviocytes and its regulation by FLIP and caspase 8 signaling. Arthritis Rheum 2006; 54: 1473-81.
38. SCHAUB FJ, HAN DK, LILES WC et al.: Fas/ FADD-mediated activation of a specific program of inflammatory gene expression in various smooth muscle cells. Nat Med 2000; 6: 790-6.
39. ZHANG WJ, KOLTUN WA, TILBERG AF, THOMPSON JL, CHORNEY MJ: Genetic control of interleukin-4-induced activation of the human signal transducer and activator of transcription 6 signaling pathway. Human Immunol 2003; 64: 402-5.
40. LEEYH, WOO JH, CHOI SJ, JI JD, SONG GG: Association between the rs 7574865 polymorphism of STAT4 and rheumatoid arthritis: a meta-analysis. Rheumatol Int 2010; 30: 661-6.
41. REMMERS EF, PLENGE RM, LEE AT et al.: STAT4 and the risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus. N Engl J Med 2007; 357: 977-86.
42. KORMAN BD, KASTNER DL, GREGERSEN PK. REMMERS EF: STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep 2008; 8: 398-403.